WESTMINSTER, Colo., June 13 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) announced today that it has filed a
universal shelf registration statement with the Securities and Exchange
Commission (SEC) that, if declared effective by the SEC, will allow the
Company to sell, from time to time, up to $100 million of its common stock,
preferred stock, depository shares, debt securities and/or warrants, either
individually or in units, in one or more offerings. As of the date of this
release, the Company has no specific plans to offer the securities covered
by the registration statement and the Company is not required to offer the
securities in the future pursuant to the registration statement. The terms
of any offering under the registration statement will be established at the
time of the offering. Proceeds from the sale of any securities will be used
for the purposes described in a prospectus supplement filed at the time of
an offering. If and when the SEC declares this registration statement
effective, the Company intends to retire the unused portion of its previous
shelf registration statement that was declared effective by the SEC in
2004.
The Company expects to use the net proceeds from any sale of securities
under this registration statement to fund the costs of its clinical trials
and other research and development activities, both on-going and planned,
to support the potential commercialization of EFAPROXYN in the event that
the Company obtains regulatory approval to market EFAPROXYN, and for
general corporate purposes, including working capital.
A shelf registration statement relating to these securities was filed
today with the SEC but has not yet become effective. The securities offered
by the Company pursuant to the registration statement may not be sold, nor
may offers to buy the securities be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of the securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule
designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during
radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to
whole brain radiation therapy in a pivotal Phase 3 trial in women with
brain metastases originating from breast cancer. The Company's other
product candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under investigation in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and
RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends," "plans,"
anticipates," "believes," "estimates," "predicts," "projects," "potential,"
"continue," and other similar terminology or the negative of these terms,
but their absence does not mean that a particular statement is not forward-
looking. Such forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that may cause
actual results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include, among
others, those described in the "Risk Factors" section of the Company's
Annual Report on Form 10-K for the year ended December 31, 2005 and in the
Company's other periodic reports and filings with the Securities and
Exchange Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press release.
All forward-looking statements are based on information currently available
to the Company on the date hereof, and the Company undertakes no obligation
to revise or update these forward-looking statements to reflect events or
circumstances after the date of this presentation, except as required by
law.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227,
jneiman@allos.com
|
